Penn Medicine Abramson Cancer Center


 

ASCO 2021 Highlights on Adjuvant Olaparib for Patients With gBRCA1/2 Mutations and High-Risk Early Stage BC: Review of the OlympiA Trial

3 views
September 1, 2021
0 Comments
Login to view comments. Click here to Login